Mitsubishi UFJ Asset Management Co. Ltd. Has $1.60 Million Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 21,100.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,109 shares of the company’s stock after purchasing an additional 23,000 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.07% of TransMedics Group worth $1,597,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Hager Investment Management Services LLC bought a new position in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC bought a new position in TransMedics Group during the 4th quarter worth approximately $40,000. AlphaQuest LLC acquired a new position in TransMedics Group during the fourth quarter valued at approximately $52,000. Quarry LP increased its stake in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. Finally, National Bank of Canada FI raised its holdings in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on TMDX shares. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Piper Sandler decreased their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Up 1.5 %

Shares of TMDX stock opened at $68.27 on Wednesday. The firm’s fifty day moving average price is $69.54 and its two-hundred day moving average price is $86.52. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $2.30 billion, a P/E ratio of 72.63 and a beta of 2.12.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.